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Abstract
Objectives The purpose of this study was to investigate the
ability of computed tomography texture analysis (CTTA) to
provide additional prognostic information in patients with
Hodgkin's lymphoma (HL) and high-grade non-Hodgkin's
lymphoma (NHL).
Methods This retrospective, pilot-study approved by the IRB
comprised 45 lymphoma patients undergoing routine 18F-
FDG-PET-CT. Progression-free survival (PFS) was deter-
mined from clinical follow-up (mean-duration: 40 months;
range: 10-62 months). Non-contrast-enhanced low-dose CT
images were submitted to CTTA comprising image filtration
to highlight features of different sizes followed by histogram-
analysis using kurtosis. Prognostic value of CTTA was com-
pared to PET FDG-uptake value, tumour-stage, tumour-bulk,
lymphoma-type, treatment-regime, and interim FDG-PET
(iPET) status using Kaplan-Meier analysis. Cox regression
analysis determined the independence of significantly prog-
nostic imaging and clinical features.
Results A total of 27 patients had aggressive NHL and 18 had
HL. Mean PFS was 48.5 months. There was no significant
difference in pre-treatment CTTA between the lymphoma
sub-types. Kaplan-Meier analysis found pre-treatment CTTA
(medium feature scale, p=0.010) and iPET status (p<0.001) to
be significant predictors of PFS. Cox analysis revealed that an
interaction between pre-treatment CTTA and iPET status was
the only independent predictor of PFS (HR: 25.5, 95% CI:
5.4-120, p<0.001). Specifically, pre-treatment CTTA risk
stratified patients with negative iPET.
Conclusion CTTA can potentially provide prognostic infor-
mation complementary to iPET for patients with HL and ag-
gressive NHL.
Key Points
• CT texture-analysis (CTTA) provides prognostic information
complementary to interim FDG-PET in Lymphoma.
• Pre-treatment CTTA and interim PETstatus were significant
predictors of progression-free survival.
• Patients with negative interim PETcould be further stratified
by pre-treatment CTTA.
• Provide precision surveillance where additional imaging
reserved for patients at greatest recurrence-risk.
• Assists in risk-adapted treatment strategy based on interim
PET and CTTA.
Keywords Positron emission tomography and Computed
tomography . Progression-free survival . Texture analysis .
Risk stratification . Lymphoma
Introduction
18F-Fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET)–computed tomography (CT) is the standard imag-
ing assessment at the end of treatment for patients with
Hodgkin’s lymphoma (HL) and diffuse large B-Cell lympho-
ma (DLBCL) [1, 2], and is also recommended for initial stag-
ing. Additional interim PET (iPET) examinations are increas-
ingly performed in clinical practice, typically after two cycles
of treatment. The aims of iPETare to confirm the effectiveness
* B. Ganeshan
b.ganeshan@ucl.ac.uk
1 Institute of Nuclear Medicine, University College London, Euston
Rd, London, UK
2 Human Health Division, Nuclear Medicine and Diagnostic Imaging
Section, International Atomic Energy Agency (IAEA),
Vienna, Austria
Eur Radiol (2017) 27:1012–1020
DOI 10.1007/s00330-016-4470-8
of treatment and exclude progressive disease. Metabolic re-
sponse demonstrated by PET-CT occurs earlier than anatom-
ical response, and multiple studies have shown that iPET is a
strong prognostic indicator in HL and aggressive non-
Hodgkin’s lymphoma (NHL), outperforming the Prognostic
Score and International Prognostic Index [3].
To date, the use of CT in lymphoma has been limited to the
anatomical assessment of disease sites and, in conjunction
with PET, for attenuation correction and localization of sites
of tracer activity. However, studies in a range of other tumours
have shown that, with appropriate quantitative image analysis,
CT can also provide prognostic information [4–11]. One such
analysis method is CT texture analysis (CTTA), which can be
applied to images that are acquired in routine clinical practice,
including the low-dose CT component of PET-CT [12]. The
ability to obtain additional prognostic information from
existing images is particularly pertinent for patients with lym-
phoma, many of whom are cured at a relatively young age and
who therefore are exposed to the risk of developing a
radiation-induced second cancer. Therefore, the aim of our
study is to investigate the ability of CTTA applied to the
low-dose CT component of pre-treatment PET-CT to provide
additional prognostic information with specific reference to
progression-free survival (PFS) in patients with Hodgkin’s
and high-grade non-Hodgkin’s lymphoma, in comparison to
FDG uptake on PET and other clinical markers.
Materials and methods
Patients
An institutional review board waiver was obtained for this
retrospective study analysis since for this type of study formal
ethical approval is not required. Informed consent was obtain-
ed from all individual participants included in the study. This
single-institution pilot study used archived patient data previ-
ously obtained in routine diagnostic practice. Consecutive pa-
tients diagnosed with pathologically proven, newly diagnosed
Hodgkin’s or high-grade non-Hodgkin’s lymphoma and treat-
ed at our institution from 2007 to 2013 were identified from
the institutional lymphoma database. Inclusion criterion was
that subjects were newly diagnosed Hodgkin’s or high-grade
non-Hodgkin’s lymphoma patients who had a pre-treatment
PET-CT scan performed before chemotherapy. Based on the
above inclusion criterion, 45 patients were included in our
study population (20 men and 25 women, mean age: 52, age
range 22–81 years).
Image acquisition
Following a 6-hour fast, patients received an intravenous in-
jection of 370MBq FDG. A standard uptake period of 60
minutes after FDG injection was used. All imaging was per-
formed on an integrated PET-CTscanner combining PETwith
a 64-slice multi-detector CT (VCT-XT Discovery, GE
Healthcare, Amersham, UK). Low-radiation-dose CTwithout
intravenous contrast agent for attenuation correction was per-
formed from the skull base to upper thighs using the following
parameters: 140 kV, 80 mAs, 0.8 s rotation time, pitch 1.5, 5-
mm slice thickness, 5-mm collimation, FOV 400 mm, matrix
size 512 x 512 and pixel resolution 0.98mm x 0.98mm. Axial
CT slices were reconstructed with standard filter kernel and
lung algorithms. The PET emission scan was obtained over
the same anatomical area (vertex to mid thighs). All acquisi-
tions were carried out in two-dimensional mode (2-D),
consisting of an emission scan of 4 minutes per bed position.
PET images were reconstructed using CT for attenuation cor-
rection by employing CT maps. Transaxial emission images
of 5.47 × 5.47 × 3.27 mm (in plane matrix size 128 × 128)
were reconstructed using ordered subsets expectation maximi-
zation (OSEM) with two iterations and 28 subsets. The axial
field-of-view was 148.75 mm. The protocol of pre-treatment,
interim (between 2-4 cycles of chemotherapy to assess re-
sponse) and post-treatment (within 4 weeks following treat-
ment to assess response) PET-CT imaging was performed
using the above-described acquisition protocol for all the pa-
tients in our study. For the purpose of image analysis only the
pre-treatment PET-CT was used to derive CTTA and PET
FDG uptake.
Image analysis (considering only the pre-treatment
PET-CT scan)
Multi-parametric PET-CT image analysis comprised
filtration-histogram-based CT texture analysis (CTTA—kur-
tosis at different spatial scale filters) and PET FDG uptake
(maximum standardized uptake value: SUVmax). Multiple le-
sions (up to five per patient, selected on the basis of most avid
lesions on PET scan,) were analyzed for CTTA and PET FDG
uptake for each patient. The average value of all the available
lesions in a patient was considered as the representative CTTA
and PET FDG uptake measurement for that particular patient.
Each image data set was analyzed independently by operators
blinded to the analysis results of the other data sets. Tumour
regions of interest (ROIs) were drawn freehand, enclosing the
lesion on the PET-CT displaying the axial image slice with the
largest cross-section dimension of the lymphoma tumour
using a standardized procedure so that ROIs were comparable
in terms of anatomical location for all data sets, as described
below.
FDG PET-CT
The PET study and non-enhanced CT were viewed indepen-
dently and as co-registered studies by a nuclear medicine
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physician (with > 10 years’ experience) using a commercial
workstation (Advantage Windows 4.4, GE Healthcare).
SUVmax, values for the entire tumour volume were obtained
for each patient using an automated thresholding method
(Fig. 1) [13, 14].
CT texture analysis (CTTA)
CT texture analysis (CTTA) was performed using TexRAD
(TexRAD Ltd, www.texrad.com, Cambridge, UK part of
Feedback Plc www.fbk.com), a proprietary commercial
research software algorithm [15–17]. The texture within
lymphoma tumours was assessed by a physician by
constructing tumour ROIs on CT, under the supervision of
an imaging researcher (with > 9 years’ of experience in
CTTA) and a dual accredited Radiologist/Nuclear Medicine
specialist (with > 10 years’ of PET-CT experience). Tumour
ROIs constructed on the CT images were further refined by an
automatic contouring procedure that excluded gas from the
ROI by removing any pixels with attenuation values below -
50 Hounsfield units (Fig. 1). Mean ROI size was 1890 pixels
(range, 113-21175 pixels). CTTA comprised an image
filtration-histogram approach where texture within the tumour
ROI was quantified following Laplacian of Gaussian (LoG)
band-pass (non-orthogonal) spatial-scale image filtration
(SSF) to highlight features ranging from approximately
2mm (fine) to 6mm (coarse) in radius; 3–5mm in radius cor-
responds to medium-texture scales. Histogram analysis com-
prised quantifying kurtosis (k) of the tumour pixels with and
without filtration (as a control). This parameter, summarized
in Eq. 1, reflects peakedness and tailedness (in another term,
the Bsharpness^) of the histogram.
k ¼
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ā is the mean value and sd is the standard-deviation within
R, R is the ROI within the image a(x,y), and n is the total
number of pixels in R. The kurtosis value can be positive or
negative. A positive kurtosis indicates a histogram that is more
peaked than a Gaussian (normal) distribution. A negative kur-
tosis indicates that histogram is flatter than a Gaussian
(normal) distribution. Filtration-histogram-based CT texture
analysis makes the process of image-quantification intuitive
to imaging practice (important for clinical-acceptance)
and at the same-time, an Bobjective^ way of quantifying
heterogeneity. The filtration step extracts features of dif-
ferent sizes followed by histogram quantification. A re-
cent article describes what the filtration-histogram tech-
nique of CTTA actually means in terms of image fea-
tures [12]. In terms of image features, kurtosis is in-
versely related to the number of objects highlighted
(whether bright or dark), and in some instances kurtosis
is increased by intensity variations in highlighted ob-
jects. Thus, the combination of filtration-histogram
(e.g. kurtosis) technique could reflect the three compo-
nents of heterogeneity—objects/features of different
sizes, numbers, and intensity variation in relation to
the background/parenchyma of the tumour/tissue.
Therefore, kurtosis post-filtration could be good enough
to give an overall description of Bheterogeneity .^
Another reason for not looking at several other reported
texture quantifications is the fact that looking at a large
number of quantifications could lead to higher false dis-
covery rate purely by chance because of multiple statis-
tical tests involved in assessing individual parameter
significance. Kurtosis post-filtration has also been
shown to be associated with overall survival in other
cancers such as colorectal and oesophageal cancers on
CT [8, 9].
Clinical parameters
Tumour stage (Ann Arbor), bulk (sum of individual lesion
areas expressed as number of pixels), type of lymphoma, treat-
ment (standard or non-standard chemotherapy regime), and
iPET findings were derived to further assess the ability of these
clinical parameters to predict progression-free survival (PFS).
Standard chemotherapy was defined as R-CHOP 21 (ritux-
imab–cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone) for diffuse, large B-cell lymphoma (DLBCL),
ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
for Hodgkin’s lymphoma. Standard chemotherapy for
Burkitt’s lymphoma was defined as R-CODOX (rituximab–
cyclophosphamide, vincristine, doxorubicin, and methotrex-
ate)/M-IVAC (etopisde, ifosamide, and cytarabine). Standard
chemotherapy for T-cell lymphoma was R-CHOP. Of the 45
patients, 11 of them (DLBCL, n=4, Burkitt’s, n=1, T-cell lym-
phoma, n=1, and Hodgkin’s, n=5) had additional treatment
with radiotherapy.
iPET (after 2-4 cycles of chemotherapy) status was based
on assessment by the reporting physician and subsequent re-
view by a nuclear medicine physician (with >10 years’ expe-
rience) within a multi-disciplinary team (MDT) setting. A
score of 4 or higher on the Deauville scoring systemwas taken
as positive, whereas a score of 1–3 was taken as negative
on iPET [18].
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Follow-up
The average follow-up periodwas 40 (10-62) months from the
pre-treatment PET-CT. Progression-free survival (PFS) was
defined as the time between the date of the pre-treatment
PET-CTand the date of the last clinical follow-up (for patients
in remission) or the date of relapse/progression. All the rele-
vant clinical data, follow-up, and survival data were obtained
by a specialist cancer research nurse (with > 6 years’
experience).
Statistical analysis
For each patient, average CTTA and PET FDG uptake mea-
surements from all the lesions on the pre-treatment CT and
PET were employed for the statistical analyses. For all statis-
tical tests, a p-value less than 0.05 was considered to be sig-
nificant. A non-parametric Mann–Whitney test evaluated the
difference in the above pre-treatment PET-CT imaging
markers between the lymphoma sub-types (Hodgkin’s and
high-grade non-Hodgkin’s lymphoma). To identify the best
pre-treatment CTTA parameter (to undergo survival-analysis),
a Mann–Whitney test assessed the difference in texture be-
tween patients who relapsed from patients who did not re-
lapse. Additionally, a Mann–Whitney test also assessed the
difference in PET SUVmax between patients who relapsed
from patients who did not relapse.
Univariate optimized Kaplan-Meier analysis assessed the
ability of pre-treatment imaging (i.e., best CTTA, PET-FDG
uptake) and clinical markers (i.e., tumour-stage, bulk, lym-
phoma type, treatment, and iPET status) to predict PFS.
Differences between the Kaplan Meier survival curves were
evaluated by a non-parametric log–rank test. An optimal
threshold was identified for each marker, which best separated
(lowest p value from log–rank test) the good and poor prog-
nostic patient sub-groups. Additionally, to address the multi-
ple survival comparisons (n=7) arising from the above step, a
Benjamini-Hochberg correction was employed to control the
false discovery rate at 0.05. Multivariate Cox regression anal-
ysis was undertaken by developing a model incorporating all
the significant (univariate) markers to determine which pa-
rameters and/or interactions between parameters were inde-
pendent predictors of PFS. Statistical analyses were per-
formed using IBM SPSS Statistics for Windows (version
19.0, IBM Corp. Armonk, NY).
Results
In total, 27 out of 45 patients had high-grade non-Hodgkin’s
lymphoma (DLBCL: n=19, Burkitt's: n=6, T-cell: n=2) and
the remaining 18 had Hodgkin’s lymphoma. The patient co-
hort comprised five patients with stage I, 17 with stage II, nine
with stage III, and 14 with stage IV tumours. Patients were
Fig. 1 Multi-parametric PET-CT
of non-Hodgkin lymphoma
comprising CT image (a), fused
FDG uptake on PET and CT
image (b), CT texture map
highlighting features at medium
texture scale (c), and CT texture
histogram (d)
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treated with standard (n=35) or non-standard (n=10) chemo-
therapy regimes.
In all, 37/45 patients had an iPET, seven of which were
positive (NHL=4 and HL=3) and 30 of which were negative
(NHL, n=19 and HL, n=11). Subsequently, clinical and imag-
ing follow-up identified that 12 of 45 patients had progressed
on first-line treatment. The mean (95 % confidence interval)
PFS was 48.5 (41.9-55.2) months.
A total of 151 (non-Hodgkin’s lymphoma, n=86 and
Hodgkin’s lymphoma, n=65) target lesions were analyzed
for pre-treatment CTTA and PET FDG uptake. Mean and
standard-deviation for all the imaging (CTTA and PET FDG
uptake) parameters are summarized in Table 1.
Difference in pre-treatment PET-CT imaging markers
between Hodgkin’s and high-grade non-Hodgkin’s
Lymphoma
There was no significant difference for the different pre-
treatment CTTA measures between the lymphoma sub-types
(Hodgkin’s and high-grade non-Hodgkin’s lymphoma), but
they are generally found to be higher in the high-grade NHL
compared to in HL. However, pre-treatment PET SUVmax was
significantly different and higher in the high-grade NHL com-
pared to in HL (median SUVmax was 20.5 vs 13.2, p=0.002).
Difference in pre-treatment PET-CT imaging markers
between relapse and no relapse
There was no significant difference for the different pre-
treatment PET-CT measures between the patients who re-
lapsed and those who did not relapse, as indicated in
Table 2. Amongst the different CTTA measures, Kurtosis at
medium-texture at SSF=5mm was the best metric in terms of
differentiating between relapse and no relapse (p=0.053) and
was chosen for survival analysis.
Univariate Kaplan-Meier analysis
The ability of each imaging and clinical parameter to
predict PFS at the optimal threshold is summarized in
Table 5. After applying a Benjamini-Hochberg correc-
tion, only two parameters were significant from the uni-
variate analysis. Pre-treatment imaging marker (CTTA:
Kurtosis at medium-texture—SSF=5mm, p=0.010,
Table 3, Fig. 2a) and iPET findings (p<0.001, Table 3,
Fig. 2b) were the only predictors of PFS. Baseline PET
FDG uptake (SUVmax), lymphoma type, bulk, stage, and
treatment were not significant predictors of PFS
(Table 3).
Multivariate Cox regression analysis
Including only parameters significantly prognostic on univar-
iate analysis (pre-treatment CTTA, medium Kurtosis, and
iPETstatus) along with their interactions, Cox regression anal-
ysis indicated that a combination of pre-treatment CTTA and
iPETstatus was the only independent predictor of PFS (hazard
ratio, HR=25.5, 95 % CI=5.4 – 120, p<0.001). Specifically
this combination was able to identify among patients with
negative iPET (n=30) two sub-groups: a sub-group (n=14)
with lower kurtosis values at CTTA (mean (range) : -0.16 (-
0.86 - 0.28)) experienced longer mean PFS (59.0 months,
Fig. 3) while the other sub-group (n=16) demonstrated higher
kurtosis values at CTTA (mean (range) : 2.18 (0.32 - 6.41))
and shorter mean PFS (41.3 months, Fig. 3). CTTA was not
discriminatory for patients with positive findings at interim
scan. These patients recorded the highest kurtosis values at
CTTA (mean (range): 2.40 (0.72 - 4.59)) and the shortest
mean PFS (7.3 months, Fig. 3). Furthermore, no relapses were
observed in the lower-risk group within the 40-month mean
follow-up period compared to a relapse rate of 31 % in the
intermediate risk group and 71% in the higher risk group (i.e.,
for patients with positive iPET).
Discussion
The results from our pilot study demonstrate a potential asso-
ciation between pre-treatment CTTAvalues from non-contrast
enhanced tumour images and progression-free survival (PFS)
in patients with HL and aggressive NHL. Pre-treatment CTTA
was shown to be a significant predictor of PFS. The other
clinical markers (pre-treatment SUV, lymphoma type, stage,
and treatment) were not found to be significant predictors of
PFS, perhaps owing to the small size of the study population.
Our study also indicates the potential for baseline CTTA on
pre-treatment staging scan to complement the prognostic val-
ue of iPET, as the only independent predictor of PFS on
Table 1 Mean and standard-deviation (SD) of all the imaging param-
eters employed in the study
Tumour characteristic Mean SD
CTTA (Kurtosis)
Without-filtration 2.77 7.95
Fine (SSF=2 mm radius) 1.01 1.72
Medium (SSF=3 mm radius) 1.23 1.86
Medium (SSF=4 mm radius) 1.22 1.80
Medium (SSF=5 mm radius) 1.18 1.82
Coarse (SSF=6 mm radius) 1.01 1.98
PET (FDG-uptake)
SUVmax 22.14 16.77
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multivariate analysis was a combination of pre-treatment
CTTA and iPET status. Pre-treatment CTTA was able to fur-
ther stratify patients based on their iPETstatus. Those patients
with a negative iPET who had a beneficial pre-treatment
CTTA had no relapses, whereas those with a negative iPET
who had adverse baseline CTTA had higher relapse rates de-
spite achieving negative iPET status.
Many studies have confirmed the importance of FDG-PET
and PET-CT for staging and response assessment in lympho-
ma [1–3, 18–24]. Recently, a few studies have highlighted the
potential of texture analysis in lymphoma for computer-aided
staging/diagnosis and as a treatment response marker using
the CT component of PET-CT, contrast-enhanced CT, and
magnetic resonance imaging (MRI); however, data is very
limited [25–27]. The study in pre- and post-chemotherapy
on contrast-enhanced CT in patients with HL demonstrated
the ability of texture features combined with classical CT pa-
rameters to be potentially useful in identifying complete re-
sponders [27]. Our pilot study focused on using the low-dose
CT (component of PET-CT) texture analysis in HL and
aggressive NHL lesions as a prognostic marker assessing
progression-free survival.
There have been no studies reporting pathological/
biological correlates for CTTA in lymphoma, an important
aspect as part of validating imaging biomarkers. One possible
correlate for CTTA is fibrosis, which has been shown to be a
significant component of lymphoma with variable patterns of
fibrosis described between lymphoma sub-types [28].
A recent study has suggested that fibrosis within lymphoma
may be related to treatment response [29]. Sieren et al [30]
have further shown a correlation between CTHounsfield units
(HU) and histology, particularly higher HU on CT is associ-
ated with fibrosis in lung cancer. It is feasible that CTTA
evaluates attenuation variations resulting from different pat-
terns of fibrosis. Computer simulations have characterized the
relationship between CT image features and the texture pa-
rameter used in our study (kurtosis) [12]. The finding that this
parameter is associated with shorter PFS in our study of lym-
phoma patients is concordant with studies that have shown the
same CTTA parameter to be significantly associated with
Table 2 Summary of the median
values of the pre-treatment PET-
CT imaging markers within the
lymphoma patients who relapsed
and did not relapse, and the
corresponding p-values from
Mann–Whitney test
Tumour characteristic Median p-value (Mann Whitney)
Relapse No relapse
CTTA (Kurtosis)
Without filtration 1.28 0.58 0.170
Fine (SSF=2 mm radius) 0.68 0.45 0.281
Medium (SSF=3 mm radius) 1.28 0.47 0.186
Medium (SSF=4 mm radius) 0.86 0.33 0.091
Medium (SSF=5 mm radius) 1.13 0.16 0.053
Coarse (SSF=6 mm radius) 1.35 0.01 0.111
PET (FDG-uptake)
SUVmax 20.4 17.2 0.178
Table 3 Summary of univariate
Kaplan-Meier survival analysis
for each imaging and clinical
markers in order of significance
(lowest p value from log-rank test
first), and the corresponding
Benjamini-Hochberg corrected p
values. P-values highlighted in














iPET status (0 – negative & 1 –
positive)
>0 15.6 (7) 56.0 (30) <0.001 0.007
CTTA (Kurtosis)
Medium (SSF=5 mm radius) >0.28 41.3 (27) 59.0 (18) 0.010 0.014
PET (FDG-uptake)
SUVmax >12.36 45.0 (36) - (9) 0.051 0.021
Type (0 – Hodgkin & 1 – non-
Hodgkin)
>0 44.0 (27) 56.1 (18) 0.060 0.029
Stage >II 38.0 (23) 53.9 (22) 0.188 0.036
Treatment (0 – non-standard &
1 – standard)
>0 46.3 (35) 44.0 (10) 0.211 0.043
Bulk (number of pixels) >18823 38.6 (23) 40.8 (22) 0.531 0.050
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survival in colorectal and oesophageal cancers [8, 9]. Texture
quantified as kurtosis has also shown to benefit from relative
insensitivity to variations in CT acquisition parameters [31]
and favorable test-retest performance on MRI [32].
Limitations of our preliminary study include the relatively
small sample size of the patient population and mixed nature
of lymphoma subtypes (Hodgkin’s and aggressive non-
Hodgkin’s lymphoma). However, combining these lymphoma
sub-types can be justified by that fact that there was no signif-
icant difference in CTTA values between Hodgkin’s and ag-
gressive non-Hodgkin’s lymphoma in our study.
We did not assess texture on interim CT scans for two
reasons. Firstly, not all patients had interim PET scans. Also
a large proportion of iPET scans were negative and, in many
of these, the nodal disease had resolved or was, using the low-
dose CT, impossible to reliably delineate with CT. Early treat-
ment changes in tumour texture, however, provides another
potential useful and important responsemarker requiring eval-
uation in further, larger studies.
It was not possible to assess whether baseline CTTA was
able to predict, as it could in those with negative iPET, an
outcome in patients with positive iPET scans. There were a
small number of patients with positive iPETwho had uniform-
ly poor outcomes, which precluded this analysis. As iPET has
low or variable reported positive predictive value in DLBCL,
this would be useful to investigate in future studies.
Quantification of changes in tumour FDG using % reduction
in SUVmax values or other functional markers such as total
lesion glycolysis and metabolic tumour volume may be nec-
essary to optimize the prognostic performance of iPET,
Fig. 2 Kaplan Meier curves showing the proportion of patients without disease progression for (a) CTTA (Kurtosis at medium-texture SSF=5mm
radius, p=0.010) and (b) status at the interim PET (p<0.001)
Fig. 3 Kaplan Meier curves
showing the proportion of
patients without disease
progression for the best parameter
from the multivariate Cox
regression analysis, i.e., CTTA
(Kurtosis at medium-texture
SSF=5mm radius)* status at the
interim PET (p<0.001)
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particularly in DLBCL [33–35], and may help reduce false-
positive findings relative to visual assessment alone. This was
not assessed in our study, as uptake times for all scans were
not strictly controlled.
Our pilot data merits further evaluation of the utility of
CTTA in larger multi-center studies. Incorporation within
existing and future randomized clinical trials focused on
risk-adapted treatment strategy based on iPET-CT would fur-
ther be a potentially attractive approach. Future studies could
also assess the complementary value of CTTA and iPET in
different types of lymphoma as well as evaluate CTTAvalues
between baseline and interim PET examinations.
Conclusion
In conclusion, this pilot study has demonstrated that CT-based
texture analysis can potentially provide prognostic informa-
tion that is complementary to interim FDG-PET for patients
with Hodgkin’s and aggressive non-Hodgkin’s lymphomas.
By analyzing the low-dose CT component of PET-CT ac-
quired in routine clinical practice, CTTA entails no additional
radiation exposure and can be readily incorporated into clini-
cal workflows.
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